Detailed Information on Tumor Mutational Burden
Our tumour mutational load assay has been designed in response to the need to determine if treatment utilising immune checkpoint inhibitors are likely to be of benefit in your particular clinical circumstances. In some cancer types, the available drugs for this treatment are not listed on the Australian Pharmaceutical Benefits Scheme, and they would incur a large out-of-pocket expense.
We consider this test an important step in gaining as much information as possible prior to making a decision on whether to progress with these particular group drugs. Our report collates available information, previously identified through histology and combined with and genetic analysis of 409 cancer driver genes, may provide a likelihood of response. Although, this area is still evolving, scientific literature suggests that the tumour mutational load assay may be beneficial in the clinical cancer setting.